Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model

Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. An autologous immunotherapy produced from resected tumors, was eval...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-04, Vol.39 (4), p.1699-1703
Main Authors: Crossley, Rachel A, Matz, Alyssa, Dew, Terry, Kalinauskas, Ashley, Faucette, Nicole, Poff, Brad, Silbart, Lawrence K, Suckow, Mark A
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Animal models
Animals
Antigens, Neoplasm - administration & dosage
Antigens, Neoplasm - immunology
Antigens, Neoplasm - toxicity
Cancer
Cancer immunotherapy
Cancer vaccines
Cancer Vaccines - administration & dosage
Cancer Vaccines - immunology
Cancer Vaccines - toxicity
Dog Diseases - diagnosis
Dog Diseases - immunology
Dog Diseases - surgery
Dog Diseases - therapy
Dogs
Extracellular matrix
Female
Fever
Immunotherapy
Immunotherapy - adverse effects
Immunotherapy - veterinary
Intestinal Mucosa - immunology
Intestine
Intestine, Small - immunology
Lethargy
Male
Margins of Excision
Metastases
Neoplasm, Residual
Neoplasms - diagnosis
Neoplasms - immunology
Neoplasms - therapy
Neoplasms - veterinary
Patients
Safety
Sus scrofa
Tissues
Tumors
Vaccination
Vaccines
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous work in rodent models showed that an autologous tissue vaccine is both a safe and effective approach for treating cancer; however, as a translational step, safety must first be evaluated in a more clinically-relevant model. An autologous immunotherapy produced from resected tumors, was evaluated in a clinically-relevant canine model to assess safety. Ninety-three dogs with spontaneously occurring tumors received vaccination with inactivated autologous tumor tissue combined with an adjuvant of particulate porcine small intestinal submucosa extracellular matrix (SIS-ECM). Patients were followed to assess the occurrence of adverse events, overall survival, and tumor recurrence and/or metastasis. A small number (12%) of patients experienced limited, mild pyrexia, injection site swelling, or lethargy, all resolving without clinical intervention. Autologous whole cell cancer immunotherapy can be used safely in the canine model of cancer and represents a safe approach for the treatment for cancer.
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13275